#ViiV Healthcare

An analysis of 15,000 insured people with HIV also confirmed past findings that single-tablet regimens are associated with higher adherence.

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.

“As Much As I Can” returns with a new format but the same powerful messages.

Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Who got what and why? NMAC’s Paul Kawata addresses criticism and breaks down the data.

A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.

The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.

Nearly $200 million of the pledge will go to DREAMS programs in Africa and the Caribbean.

ViiV Healthcare and GlaxoSmithKline are jointly developing GSK3640254.

Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.

The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.

Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.